Correction: ContextVision AB: Result of the offer to buy back own shares

18 Dec 2024 11:55 CET

Stockholm, Dec 18, 2024

A correction is made to the press release published today, December 18, 2024, at
08.10 AM, regarding the number of shares resolved to be bought back by the
company. A number of 35,722 shares were not included in the previous press
release, the correct press release is as follows.

Reference is made to the stock exchange announcement on December 13th, 2024, in
which ContextVision AB (publ) ("ContextVision" or the "Company") launched an
offer to buy back up to 3,000,000 shares in the Company for a total amount of up
to NOK 15,000,000 (the "Offer").

The application period for the Offer ended on December 17th, 2024 at 16:30 CET.
Following the end of the application period, the Company has resolved to buy
back 1,241,457 shares in the Company at a price of NOK 6.50 per share, amounting
to a total of NOK 8,069,470.50.

All offers to sell shares with limits at or below NOK 6.50 have been fully
allocated.

Allocation notifications are expected to be sent to the shareholders who
tendered shares in the Offer on or about December 18th, 2024. The trade date is
expected to be on or about 18 December 2024 with the settlement date expected on
or about December 20th, 2024.

The settlement will be conducted on a normal delivery-versus-payment basis.
Following the settlement of the Offer, the Company will own 1,241,457 shares in
the Company. The Company currently has 77,367,500 shares outstanding.

This stock exchange announcement is published in accordance with the disclosure
requirements in Section 5-12 of the Norwegian Securities Trading Act. This stock
exchange announcement was published by Richard Hallström, CFO, on the time and
date provided.

For more information, please contact:

Carnegie AS: contextvision@carnegie.no or +47 22 00 93 40

Richard Hallström, CFO: richard.hallstrom@contextvision.com

About ContextVision

ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X
-ray and MRI equipment around the world. Our expertise is to develop powerful
software products, based on proprietary technology and artificial intelligence
for image-based applications. Our cutting-edge technology helps clinicians
accurately interpret medical images, a crucial foundation for better diagnosis
and treatment. The company, established in 1983, is based in Sweden with local
representation in the U.S., Japan, China and Korea. ContextVision is listed on
the Oslo Stock Exchange under the ticker CONTX.

More information:
Access the news on Oslo Bors NewsWeb site